Work

Safety and Efficacy of FT522, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy with Alloimmune Defense Receptor (ADR) in Relapsed/Refractory B-Cell Lymphoma

Year: 2024

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2024-198684

Authors: Veronika Bachanova, Abhinav Deol, Taha Mahdi Salih Al-Juhaishi, Premal D. Lulla, Michael T. Byrne, Carol Wong, Cara Bickers, Trever Greene, Lilly Wong, Bertha Villa, Deepa Patel, Bahram Bob Valamehr, Rebecca Elstrom, Matthew Lunning

Institutions: University of Minnesota, Wayne State University, The Barbara Ann Karmanos Cancer Institute, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Houston Methodist, Baylor College of Medicine, Texas Children's Hospital, Tennessee Oncology, Fate Therapeutics (United States), Nebraska Medical Center, University of Nebraska Medical Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4405048838

Cites:

Cited by: 14

Related to: 10